drugset
drugset / Trial / NCT07122687

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

NCT07122687 ↗

Phase 2 Recruiting 170 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.

Timeline

Start
2025-08-26
Primary completion
2026-11-30
Completion
2030-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI363 Protein / enzyme biologic 1.5 mg/kg Intravenous
Comparator Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma